# Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer

> **NCT07488884** · PHASE1 · NOT_YET_RECRUITING · sponsor: **ImmunityBio, Inc.** · enrollment: 30 (estimated)

## Conditions studied

- Pancreatic Cancer Resectable
- Pancreatic Cancer

## Interventions

- **DRUG:** Nogapendekin Alfa Inbakicept (N803)
- **DRUG:** Sotevtamab
- **DRUG:** Zabadinostat (CXD101)
- **DRUG:** Nab paclitaxel / gemcitabine

## Key facts

- **NCT ID:** NCT07488884
- **Lead sponsor:** ImmunityBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2027-06-01
- **Final completion:** 2029-06-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07488884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07488884, "Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07488884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*